Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 650

1.

Combination therapies of Artemisinin and its derivatives as a viable approach for future cancer treatment.

Kumar MS, Yadav TT, Khair RR, Peters GJ, Yergeri MC.

Curr Pharm Des. 2019 Sep 2. doi: 10.2174/1381612825666190902155957. [Epub ahead of print]

PMID:
31475891
2.

The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies.

El Hassouni B, Granchi C, Vallés-Martí A, Supadmanaba IGP, Bononi G, Tuccinardi T, Funel N, Jimenez CR, Peters GJ, Giovannetti E, Minutolo F.

Semin Cancer Biol. 2019 Aug 21. pii: S1044-579X(19)30180-4. doi: 10.1016/j.semcancer.2019.08.025. [Epub ahead of print] Review.

PMID:
31445217
3.

Breastfeeding during R-CHOP chemotherapy: please abstain!

Codacci-Pisanelli G, Honeywell RJ, Asselin N, Bellettini G, Peters GJ, Giovannetti E, Peccatori FA.

Eur J Cancer. 2019 Sep;119:107-111. doi: 10.1016/j.ejca.2019.07.012. Epub 2019 Aug 19. No abstract available.

PMID:
31437753
4.

Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell Lines.

Noordhuis P, Laan AC, van de Born K, Honeywell RJ, Peters GJ.

Int J Mol Sci. 2019 Jul 24;20(15). pii: E3619. doi: 10.3390/ijms20153619.

5.

Biological Evaluation of the Antiproliferative and Anti-migratory Activity of a Series of 3-(6-Phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-1H-indole Derivatives Against Pancreatic Cancer Cells.

Li Petri G, Cascioferro S, El Hassouni B, Carbone D, Parrino B, Cirrincione G, Peters GJ, Diana P, Giovannetti E.

Anticancer Res. 2019 Jul;39(7):3615-3620. doi: 10.21873/anticanres.13509.

PMID:
31262887
6.

Uridine Cytidine Kinase 2 as a Potential Biomarker for Treatment with RX-3117 in Pancreatic Cancer.

El Hassouni B, Infante J, Mantini G, Ricci C, Funel N, Giovannetti E, Peters GJ.

Anticancer Res. 2019 Jul;39(7):3609-3614. doi: 10.21873/anticanres.13508.

PMID:
31262886
7.

From 'Targeted Therapy' to Targeted Therapy.

Peters GJ.

Anticancer Res. 2019 Jul;39(7):3341-3345. doi: 10.21873/anticanres.13476. Review.

PMID:
31262854
8.

To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology.

El Hassouni B, Mantini G, Li Petri G, Capula M, Boyd L, Weinstein HNW, Vallés-Marti A, Kouwenhoven MCM, Giovannetti E, Westerman BA, Peters GJ; EORTC PAMM Group.

Anticancer Res. 2019 Jul;39(7):3303-3309. doi: 10.21873/anticanres.13472. Review.

PMID:
31262850
9.

Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine.

Van Den Borg R, Leonetti A, Tiseo M, Giovannetti E, Peters GJ.

Expert Rev Anticancer Ther. 2019 Jun;19(6):461-471. doi: 10.1080/14737140.2019.1624530. Epub 2019 May 31.

PMID:
31148500
10.

Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line.

Van Der Steen N, Leonetti A, Keller K, Dekker H, Funel N, Lardon F, Ruijtenbeek R, Tiseo M, Rolfo C, Pauwels P, Peters GJ, Giovannetti E.

Biochem Pharmacol. 2019 Aug;166:128-138. doi: 10.1016/j.bcp.2019.05.014. Epub 2019 May 10.

PMID:
31078602
11.

Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells.

Firuzi O, Che PP, El Hassouni B, Buijs M, Coppola S, Löhr M, Funel N, Heuchel R, Carnevale I, Schmidt T, Mantini G, Avan A, Saso L, Peters GJ, Giovannetti E.

Cancers (Basel). 2019 May 8;11(5). pii: E638. doi: 10.3390/cancers11050638.

12.

RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment.

Balboni B, El Hassouni B, Honeywell RJ, Sarkisjan D, Giovannetti E, Poore J, Heaton C, Peterson C, Benaim E, Lee YB, Kim DJ, Peters GJ.

Expert Opin Investig Drugs. 2019 Apr;28(4):311-322. doi: 10.1080/13543784.2019.1583742. Epub 2019 Mar 16. Review.

PMID:
30879349
13.

Folate receptors and transporters: biological role and diagnostic/therapeutic targets in cancer and other diseases.

Frigerio B, Bizzoni C, Jansen G, Leamon CP, Peters GJ, Low PS, Matherly LH, Figini M.

J Exp Clin Cancer Res. 2019 Mar 12;38(1):125. doi: 10.1186/s13046-019-1123-1.

14.

Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?

Peters GJ, Giovannetti E, Honeywell RJ, Ciccolini J.

Br J Clin Pharmacol. 2019 Jun;85(6):1213-1214. doi: 10.1111/bcp.13921. Epub 2019 Apr 23. No abstract available.

15.

Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation.

Jaramillo AC, Cloos J, Lemos C, Stam RW, Kaspers GJL, Jansen G, Peters GJ.

Leuk Res. 2019 Apr;79:45-51. doi: 10.1016/j.leukres.2019.02.008. Epub 2019 Feb 23.

PMID:
30849662
16.

E-drug delivery: a futuristic approach.

Yadav KS, Kapse-Mistry S, Peters GJ, Mayur YC.

Drug Discov Today. 2019 Apr;24(4):1023-1030. doi: 10.1016/j.drudis.2019.02.005. Epub 2019 Feb 19. Review.

PMID:
30794860
17.

DNA methyltransferases expression in normal tissues and various human cancer cell lines, xenografts and tumors.

Honeywell RJ, Sarkisjan D, Kristensen MH, de Klerk DJ, Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2018;37(12):696-708. doi: 10.1080/15257770.2018.1498516. Epub 2019 Jan 19.

PMID:
30663502
18.

Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor.

Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2018;37(12):666-678. doi: 10.1080/15257770.2018.1508692. Epub 2019 Jan 19.

PMID:
30663496
19.

Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors.

Rovithi M, Gerritse SL, Honeywell RJ, Ten Tije AJ, Ruijter R, Peters GJ, Voortman J, Labots M, Verheul HMW.

J Clin Oncol. 2019 Feb 10;37(5):411-418. doi: 10.1200/JCO.18.00725. Epub 2018 Dec 26.

20.

Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.

Sciarrillo R, Wojtuszkiewicz A, El Hassouni B, Funel N, Gandellini P, Lagerweij T, Buonamici S, Blijlevens M, Zeeuw van der Laan EA, Zaffaroni N, Deraco M, Kusamura S, Würdinger T, Peters GJ, Molthoff CFM, Jansen G, Kaspers GJL, Cloos J, Giovannetti E.

EBioMedicine. 2019 Jan;39:215-225. doi: 10.1016/j.ebiom.2018.12.025. Epub 2018 Dec 20.

21.

Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance.

de Klerk DJ, Honeywell RJ, Jansen G, Peters GJ.

Cancers (Basel). 2018 Dec 10;10(12). pii: E503. doi: 10.3390/cancers10120503. Review.

22.

Targeting the ribosome biogenesis key molecule fibrillarin to avoid chemoresistance.

El Hassouni B, Sarkisjan D, Vos JC, Giovannetti E, Peters GJ.

Curr Med Chem. 2018 Dec 3. doi: 10.2174/0929867326666181203133332. [Epub ahead of print]

PMID:
30501594
23.

Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.

Tibaldi C, Camerini A, Tiseo M, Mazzoni F, Barbieri F, Vittimberga I, Brighenti M, Boni L, Baldini E, Gilli A, Honeywell R, Chartoire M, Peters GJ, Giovannetti E; Italian Oncological Group of Clinical Research (GOIRC).

Br J Cancer. 2018 Nov;119(11):1326-1331. doi: 10.1038/s41416-018-0307-3. Epub 2018 Nov 8.

PMID:
30405211
24.

Proton-coupled folate transporter as a biomarker of outcome to treatment for pleural mesothelioma.

Petri GL, Cascioferro S, Parrino B, Peters GJ, Diana P, Giovannetti E.

Pharmacogenomics. 2018 Jul 1;19(10):811-814. doi: 10.2217/pgs-2018-0071. Epub 2018 Jun 19. No abstract available.

25.

Aminopeptidase antibodies in mesothelioma: new wine deserves new sacks.

van Meerbeeck JP, Jansen G, Giovannetti E, Peters GJ.

Eur Respir J. 2018 May 24;51(5). pii: 1800817. doi: 10.1183/13993003.00817-2018. Print 2018 May. No abstract available.

PMID:
29794125
26.

Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines.

Peters GJ.

Nucleosides Nucleotides Nucleic Acids. 2018;37(6):329-339. doi: 10.1080/15257770.2018.1460479. Epub 2018 May 3.

PMID:
29723133
27.

High inter-individual variability of serum xanthine oxidoreductase activity in IBD patients.

Meijer B, Seinen ML, Hosman T, Linskens RK, Kneppelhout JK, Peters GJ, Mulder CJ, van Bodegraven AA, de Boer NK.

Nucleosides Nucleotides Nucleic Acids. 2018;37(6):317-323. doi: 10.1080/15257770.2018.1460477. Epub 2018 May 3.

PMID:
29723116
28.

Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer.

van Zweeden AA, van Groeningen CJ, Honeywell RJ, Giovannetti E, Ruijter R, Smorenburg CH, Giaccone G, Verheul HMW, Peters GJ, van der Vliet HJ.

Cancer Chemother Pharmacol. 2018 Jul;82(1):39-48. doi: 10.1007/s00280-018-3588-6. Epub 2018 Apr 25.

29.

5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer.

Toffalorio F, Santarpia M, Radice D, Jaramillo CA, Spitaleri G, Manzotti M, Catania C, Jordheim LP, Pelosi G, Peters GJ, Tibaldi C, Funel N, Spaggiari L, de Braud F, De Pas T, Giovannetti E.

Oncotarget. 2018 Feb 16;9(23):16437-16450. doi: 10.18632/oncotarget.24505. eCollection 2018 Mar 27.

30.

Elucidation of chemosensitization effect of acridones in cancer cell lines: Combined pharmacophore modeling, 3D QSAR, and molecular dynamics studies.

Gade DR, Makkapati A, Yarlagadda RB, Peters GJ, Sastry BS, Rajendra Prasad VVS.

Comput Biol Chem. 2018 Jun;74:63-75. doi: 10.1016/j.compbiolchem.2018.02.014. Epub 2018 Feb 24.

PMID:
29547875
31.

Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide.

Oerlemans R, Berkers CR, Assaraf YG, Scheffer GL, Peters GJ, Verbrugge SE, Cloos J, Slootstra J, Meloen RH, Shoemaker RH, Dijkmans BAC, Scheper RJ, Ovaa H, Jansen G.

Invest New Drugs. 2018 Oct;36(5):797-809. doi: 10.1007/s10637-018-0569-x. Epub 2018 Feb 14.

32.

Cellular pharmacology studies of anticancer agents: recommendations from the EORTC-PAMM group.

Perego P, Hempel G, Linder S, Bradshaw TD, Larsen AK, Peters GJ, Phillips RM; EORTC PAMM Group.

Cancer Chemother Pharmacol. 2018 Mar;81(3):427-441. doi: 10.1007/s00280-017-3502-7. Epub 2017 Dec 28. Review.

PMID:
29285635
33.

Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib.

Muller IB, de Langen AJ, Giovannetti E, Peters GJ.

Onco Targets Ther. 2017 Sep 13;10:4535-4541. doi: 10.2147/OTT.S109493. eCollection 2017. Review.

34.

Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools.

Giovannetti E, Zucali PA, Assaraf YG, Funel N, Gemelli M, Stark M, Thunnissen E, Hou Z, Muller IB, Struys EA, Perrino M, Jansen G, Matherly LH, Peters GJ.

Ann Oncol. 2017 Nov 1;28(11):2725-2732. doi: 10.1093/annonc/mdx499.

35.

The potential of multi-compound nanoparticles to bypass drug resistance in cancer.

Da Silva CG, Peters GJ, Ossendorp F, Cruz LJ.

Cancer Chemother Pharmacol. 2017 Nov;80(5):881-894. doi: 10.1007/s00280-017-3427-1. Epub 2017 Sep 8. Review.

36.

Acridone-pyrimidine hybrids- design, synthesis, cytotoxicity studies in resistant and sensitive cancer cells and molecular docking studies.

Murahari M, Prakash KV, Peters GJ, Mayur YC.

Eur J Med Chem. 2017 Oct 20;139:961-981. doi: 10.1016/j.ejmech.2017.08.023. Epub 2017 Aug 12.

PMID:
28886509
37.

Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN.

Cavazzoni A, La Monica S, Alfieri R, Ravelli A, Van Der Steen N, Sciarrillo R, Madeddu D, Lagrasta CAM, Quaini F, Bonelli M, Fumarola C, Cretella D, Digiacomo G, Tiseo M, Peters GJ, Ardizzoni A, Petronini PG, Giovannetti E.

Oncotarget. 2017 May 23;8(32):53068-53083. doi: 10.18632/oncotarget.18087. eCollection 2017 Aug 8.

38.

A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer.

Coppola S, Carnevale I, Danen EHJ, Peters GJ, Schmidt T, Assaraf YG, Giovannetti E.

Drug Resist Updat. 2017 Mar;31:43-51. doi: 10.1016/j.drup.2017.07.001. Epub 2017 Jul 24. Review.

PMID:
28867243
39.

Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer.

Lam SW, van der Noort V, van der Straaten T, Honkoop AH, Peters GJ, Guchelaar HJ, Boven E.

Pharmacol Res. 2018 Feb;128:122-129. doi: 10.1016/j.phrs.2017.08.005. Epub 2017 Aug 18.

PMID:
28827188
40.

Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC.

Van Der Steen N, Mentens Y, Ramael M, Leon LG, Germonpré P, Ferri J, Gandara DR, Giovannetti E, Peters GJ, Pauwels P, Rolfo C.

Clin Lung Cancer. 2018 Jan;19(1):35-41. doi: 10.1016/j.cllc.2017.06.010. Epub 2017 Jul 6. Review.

PMID:
28757336
41.

Resistance Mechanisms to AZD9291 and Rociletinib-Letter.

Van Der Steen N, Rolfo C, Pauwels P, de Langen AJ, Peters GJ, Giovannetti E.

Clin Cancer Res. 2017 Jul 15;23(14):3966. doi: 10.1158/1078-0432.CCR-17-0167. No abstract available.

42.

Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer.

Phillips RM, Hendriks HR, Sweeney JB, Reddy G, Peters GJ.

Expert Opin Drug Metab Toxicol. 2017 Jul;13(7):783-791. doi: 10.1080/17425255.2017.1341490. Epub 2017 Jul 3. Review.

PMID:
28637373
43.

Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative.

Hendriks HR, Govaerts AS, Fichtner I, Burtles S, Westwell AD, Peters GJ.

Br J Cancer. 2017 Jul 11;117(2):195-202. doi: 10.1038/bjc.2017.167. Epub 2017 Jun 13.

44.

Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate.

Rizzuto I, Ghazaly E, Peters GJ.

Pharmacogenomics. 2017 Jun;18(9):911-925. doi: 10.2217/pgs-2017-0034. Epub 2017 Jun 8. Review.

PMID:
28594276
45.

Rapid Homogeneous Immunoassay to Quantify Gemcitabine in Plasma for Therapeutic Drug Monitoring.

Kozo D, Ross MW, Jarrah J, Barrett M, Harney RL, Courtney JB, Baburina I, Holleran JL, Beumer JH, Peters GJ, Honeywell RJ, Salamone SJ.

Ther Drug Monit. 2017 Jun;39(3):235-242. doi: 10.1097/FTD.0000000000000402.

46.

Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells.

Steen NV, Potze L, Giovannetti E, Cavazzoni A, Ruijtenbeek R, Rolfo C, Pauwels P, Peters GJ.

Am J Cancer Res. 2017 Apr 1;7(4):816-830. eCollection 2017.

47.

Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer.

Giovannetti E, van der Borden CL, Frampton AE, Ali A, Firuzi O, Peters GJ.

Semin Cancer Biol. 2017 Jun;44:43-59. doi: 10.1016/j.semcancer.2017.04.006. Epub 2017 Apr 22. Review.

48.

Erratum to: Glutamate and α-ketoglutarate: key players in glioma metabolism.

Maus A, Peters GJ.

Amino Acids. 2017 Jun;49(6):1143. doi: 10.1007/s00726-017-2414-5. No abstract available.

PMID:
28417224
49.

The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures.

Narayan RS, Fedrigo CA, Brands E, Dik R, Stalpers LJ, Baumert BG, Slotman BJ, Westerman BA, Peters GJ, Sminia P.

BMC Cancer. 2017 Mar 21;17(1):204. doi: 10.1186/s12885-017-3193-9.

50.

Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer.

Massihnia D, Avan A, Funel N, Maftouh M, van Krieken A, Granchi C, Raktoe R, Boggi U, Aicher B, Minutolo F, Russo A, Leon LG, Peters GJ, Giovannetti E.

J Hematol Oncol. 2017 Jan 6;10(1):9. doi: 10.1186/s13045-016-0371-1.

Supplemental Content

Loading ...
Support Center